dirucotide
Peptideexperimental
Dirucotide (also known as MBP8298) was developed by two research scientists (Dr. Kenneth G. Warren, MD, FRCP(C) & Ingrid Catz, Senior Scientist) at the University of Alberta for the treatment of Multiple Sclerosis (MS). Dirucotide is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). The sequence of these 17 amino acids isH2N-Asp-Glu-Asn-Pro-Val-Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-OH — Wikipedia
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
4
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00869726)
Timeline
Indications
Mechanism of action
- Myelin basic proteinImmunity, desensitized
MBP immunity, desensitized
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](C)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)C(C)C- Mol. weight
- 2013.29 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDirucotide ↗
- ChEMBLCHEMBL2105639 ↗
Also known as
- dirucotide
- dirucotide
- dirucotide
- dirucotide
- dirucotide
- mbp8298
- mbp8298
- mbp8298
- mbp8298
- mbp-8298
- sf328
- sf328
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00468611 | Phase 3 | Jun 1, 2007 | BioMS Technology Corp., University of Pennsylvania |
| NCT00870155 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2007 | BioMS Technology Corp., Eli Lilly |
| NCT00869986 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2006 | BioMS Technology Corp., Eli Lilly |
| NCT00869726 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2004 | BioMS Technology Corp., Eli Lilly |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioMS Technology Corp. | For profit | 4 | 1 | 1 | 2004 |
| Eli Lilly | For profit | 3 | 3 | 1 | 2004 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1